Page 16 - For Global News Today : Breaking News, Live Updates & Top Stories | Vimarsana

“Me es grato informar que el Jurado integrado por: EDUCA, The Hunger Project México, Earth Day Network, Reversible, Centro Urbano, SDSN Youth México, determinó que la Universidad Intercultural de Chiapas ha sido favorecida a través del proyecto que estamos desarrollando como Cuerpo Académico 06: Estudios de Género e Interculturalidad”, informó en un escrito. La académica explicó que el proyecto "Restauración de Espacios, Especies y Tradiciones en Comunidades de Chiapas", es desarrollado por docentes asociados al Cuerpo Académico, entre ellos Carmen Marín Levario, Luis Galindo ...

SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for to...

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma July 29, 2021 20:40 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Na...

(1) SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for ... Junshi BiosciencesJuly 30, 2021 GMT SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) fo...